

1 **Title: High-dimensional profiling reveals phenotypic heterogeneity and disease-specific**
2 **alterations of granulocytes in COVID-19**

3

4 **Authors:** Magda Lourda^{1,2}, Majda Dzidic¹, Laura Hertwig¹, Helena Bergsten¹, Laura M. Palma
5 Medina¹, Egle Kvedaraite^{1,2}, Puran Chen¹, Jagadeeswara R. Muvva¹, Jean-Baptiste Gorin¹,
6 Martin Cornillet¹, Johanna Emgård¹, Kirsten Moll¹, Marina García¹, Kimia T. Maleki¹, Jonas
7 Klingström¹, Jakob Michaëlsson¹, Malin Flodström-Tullberg¹, Susanna Brighenti¹, Marcus
8 Buggert¹, Jenny Mjösberg¹, Karl-Johan Malmberg¹, Johan K. Sandberg¹, Jan-Inge Henter^{2,3},
9 Elin Folkesson^{4,5}, Sara Gredmark-Russ^{1,4}, Anders Sönnernborg^{4,6}, Lars I. Eriksson^{7,8}, Olav
10 Rooyackers^{8,9}, Soo Aleman^{4,6}, Kristoffer Strålin^{4,6}, Hans-Gustaf Ljunggren¹, Niklas K.
11 Björkström¹, Mattias Svensson¹, Andrea Ponzetta¹, Anna Norrby-Teglund¹, Benedict J.
12 Chambers¹; and the Karolinska KI/K COVID-19 Study Group

13

14 **Authorship note:**

15 ML, MD and LH share first authorship.

16 AP, ANT and BJC share last authorship.

17 Correspondence: Magda Lourda (magdalini.lourda@ki.se)

18

19 **Affiliations:**

20 ¹Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,
21 Karolinska University Hospital, Stockholm, Sweden

22 ²Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska
23 Institutet, Stockholm, Sweden

24 ³Theme of Children's Health, Karolinska University Hospital, Stockholm, Sweden

25 ⁴Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 ⁵Division of Infectious Diseases, Department of Medicine Solna, Karolinska Institutet,
27 Stockholm, Sweden

28 ⁶Division of Infectious Diseases and Dermatology, Department of Medicine Huddinge,
29 Karolinska Institutet, Stockholm, Sweden

30 ⁷Department of Physiology and Pharmacology, Section for Anesthesiology and Intensive Care,
31 Karolinska Institutet, Stockholm, Sweden

32 ⁸Function Perioperative Medicine and Intensive Care, Karolinska University Hospital,
33 Stockholm, Sweden

34 ⁹Department of Clinical Interventions and Technology CLINTEC, Division for Anesthesiology
35 and Intensive Care, Karolinska Institutet, Stockholm, Sweden.

36

37 **Conflict of interest statement:**

38 K-JM is a Scientific Advisor and has a research grant from Fate Therapeutics and is a member
39 of the Scientific Advisory Board of Vycellix Inc. H-GL is a member of the board of XNK
40 Therapeutics AB and Vycellix Inc. J-IH serves as consultant for Sobi AB. The remaining
41 authors have declared that no conflict of interest exists.

42

43 **Abstract**

44 Since the outset of the COVID-19 pandemic, increasing evidence suggests that the innate
45 immune responses play an important role in the disease development. A dysregulated
46 inflammatory state has been proposed as key driver of clinical complications in COVID-19,
47 with a potential detrimental role of granulocytes. However, a comprehensive phenotypic
48 description of circulating granulocytes in SARS-CoV-2-infected patients is lacking. In this
49 study, we used high-dimensional flow cytometry for granulocyte immunophenotyping in
50 peripheral blood collected from COVID-19 patients during acute and convalescent phases.
51 Severe COVID-19 was associated with increased levels of both mature and immature
52 neutrophils, and decreased counts of eosinophils and basophils. Distinct immunotypes were
53 evident in COVID-19 patients, with altered expression of several receptors involved in
54 activation, adhesion and migration of granulocytes (e.g. CD62L, CD11a/b, CD69, CD63,
55 CXCR4). Paired sampling revealed recovery and phenotypic restoration of the granulocytic
56 signature in the convalescent phase. The identified granulocyte immunotypes correlated with
57 distinct sets of soluble inflammatory markers supporting pathophysiologic relevance.
58 Furthermore, clinical features, including multi-organ dysfunction and respiratory function,
59 could be predicted using combined laboratory measurements and immunophenotyping. This
60 study provides a comprehensive granulocyte characterization in COVID-19 and reveals
61 specific immunotypes with potential predictive value for key clinical features associated with
62 COVID-19.

63 **Significance**

64 Accumulating evidence shows that granulocytes are key modulators of the immune response
65 to SARS-CoV-2 infection and their dysregulation could significantly impact COVID-19
66 severity and patient recovery after virus clearance. In the present study, we identify selected
67 immune traits in neutrophil, eosinophil and basophil subsets associated to severity of COVID-
68 19 and to peripheral protein profiles. Moreover, computational modeling indicates that the
69 combined use of phenotypic data and laboratory measurements can effectively predict key
70 clinical outcomes in COVID-19 patients. Finally, patient-matched longitudinal analysis shows
71 phenotypic normalization of granulocyte subsets 4 months after hospitalization. Overall, in this
72 work we extend the current understanding of the distinct contribution of granulocyte subsets
73 to COVID-19 pathogenesis.

74

75 **Introduction**

76 Caused by the novel coronavirus SARS-CoV-2, the current COVID-19 pandemic poses an
77 unprecedented threat to the global health systems, with over 2 million confirmed deaths
78 reported worldwide in January 2021 ([https://www.who.int/emergencies/diseases/novel-](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)
79 [coronavirus-2019](https://www.who.int/emergencies/diseases/novel-coronavirus-2019)). About 80% of COVID-19 patients present with a mild or moderate disease
80 course, while 15-20% develop severe complications (1, 2), including respiratory failure,
81 coagulation abnormalities and life-threatening acute respiratory distress syndrome (ARDS).
82 A dysregulated inflammatory state has been proposed as a key driver of clinical complications
83 of COVID-19 (3) and has been associated with increased mortality (4). High levels of several
84 pro-inflammatory mediators (e.g. Interleukin-1 β (IL-1 β), IL-6, Tumor necrosis factor α
85 (TNF α) and CXCL8) are detected early after viral infection (5), and the resolution of this
86 inflammatory response seems impaired in patients with severe disease progression (5, 6). Many
87 of these pro-inflammatory cytokines are associated with granulocyte activation and recruitment
88 (7), and it has been reported that an increased neutrophil-to-lymphocyte ratio (NLR) in
89 peripheral blood can be used as a prognostic marker of higher disease severity in COVID-19
90 patients, similar to SARS-CoV-1 and MERS (8-10).

91 The cellular components of the polymorphonuclear granulocyte family – neutrophils,
92 eosinophils and basophils – arise from a common myeloid progenitor in humans (11) and
93 represent the very first line of defense against invading microbes. The role of granulocytes in
94 viral infection has mostly been confined to neutrophils (12, 13), though eosinophils and
95 basophils have been implicated in the host response to viruses as well (14, 15). In COVID-19,
96 an increased neutrophil abundance in circulation is mirrored by a substantial enrichment of
97 granulocytes in the inflamed lung (16, 17). Several reports highlighted the presence of
98 immature neutrophils in blood of COVID-19 patients (18, 19), implying a marked emergency
99 granulopoiesis occurring in the bone marrow. The presence of immature neutrophil populations

100 is phenotypically reminiscent of granulocytic myeloid-derived suppressor cells (G-MDSCs),
101 and has thus been linked to a potential immunosuppressive role of neutrophils during SARS-
102 CoV-2 infection (19, 20). A confounding factor in many of the reported studies is represented
103 by the broad use of peripheral blood mononuclear cells (PBMC) (e.g. (6, 18, 21)), where only
104 the low-density granulocytic fraction can be captured, which could lead to an inherent bias in
105 the result interpretation (22, 23). Longitudinal studies performed during the course of SARS-
106 CoV-2 infection have revealed that neutrophil numbers slowly decrease during infection, and
107 the rate of such decrease is lower in more severe patients (6). Interestingly, basophil and
108 eosinophil counts were found to be inversely correlated with neutrophil levels (24).

109 In the present study we set out to delineate the phenotypic alterations within neutrophil,
110 eosinophil and basophil populations during the early phase of SARS-CoV-2 infection in
111 patients with acute COVID-19 and in the convalescent phase. We provide a detailed analysis
112 at the single-cell resolution of granulocyte diversity in fresh whole blood of COVID-19 patients
113 using 25-color flow cytometry, integrated with soluble factor detection by proteomics and
114 detailed clinical information. Overall, this study delineates the biological contribution of
115 granulocyte subsets to COVID-19 pathogenesis, with an emphasis on their phenotypical
116 heterogeneity in viral infection. The data reveals specific immunotypes with potential
117 predictive value for key clinical features associated with COVID-19 severity.

118

119 **Results**

120 *Altered composition of granulocyte populations is associated with disease severity in COVID-*
121 *19*

122 To provide an in-depth characterization of the granulocyte compartment in patients with
123 moderate or severe COVID-19, we designed a strategy based on the integrated analysis of high
124 dimensional flow cytometry data from whole blood cells, extensive proteomic screening in
125 serum and plasma, and detailed clinical and laboratory information from patients included in
126 the study (Figure 1A). Twenty-six hospitalized COVID-19 patients (10 moderate and 16
127 severe) and age-matched healthy controls were recruited at Karolinska University Hospital as
128 part of the Karolinska KI/K COVID-19 Immune Atlas effort (25-28) (Figure 1B, Supplemental
129 Tables 1-3). No differences in age, sex, body-mass index (BMI) or time from symptom debut
130 until hospital admission, were present between moderate and severe patients (Figure 1B,
131 Supplemental Table 2). The severe group displayed higher concentration of the inflammatory
132 markers D-dimer and C-reactive protein (CRP), coagulation and inflammatory markers, and
133 included all patients (n=4) who subsequently died in the hospital (Figure 1B).

134 A 25-color flow cytometry panel was applied on freshly isolated whole blood cells from
135 COVID-19 patients and healthy controls (Figure 1C) to identify and characterize the main
136 granulocyte subsets. To minimize batch-effects, samples were processed and acquired during
137 a short period of time (3 weeks). A manual gating strategy for neutrophils, eosinophils and
138 basophils was used based on expression of canonical lineage-defining markers (Figure 1C).
139 Neutrophils were identified as $CD15^+CD193^-CD66b^+CD16^{bright/dim}$, eosinophils as
140 $CD15^{bright/dim}CD193^{bright/dim}CD16^-FceR1^{dim}CD123^{dim/-}$ and basophils as $CD15^-$
141 $CD193^{bright}FceR1^{bright}CD123^{bright}HLA-DR^{dim/-}$. Projection of gated cells into the Uniform
142 Manifold Approximation and Projection (UMAP) space integrating all the analyzed markers
143 confirmed the efficacy of the manual gating strategy (Figure 1C).

144 The analysis of absolute leukocyte counts in COVID-19 patients highlighted relevant
145 alterations in the granulocyte compartment in peripheral blood. In particular, neutrophils were
146 significantly increased in patients with severe disease course, while eosinophils and basophils
147 were decreased in COVID-19 patients when compared to non-infected healthy controls (Figure
148 1D). A similar trend was observed in the relative frequencies of granulocyte subsets over total
149 leukocytes. A higher proportion of neutrophils in patients with moderate and severe COVID-
150 19 ($66.65 \pm 11.71\%$ and 78.96 ± 8.83 respectively) was associated with the reduction of the
151 eosinophil and basophil fractions (up to 3 and 7.5-fold, respectively, Figure 1E). The ratios of
152 neutrophils over eosinophils or basophils increased in both patient groups, while no difference
153 in the eosinophil to basophil ratios was observed between controls and patients (Supplemental
154 Figure 1A). In line with previous reports (29), we found that severe COVID-19 was associated
155 with higher neutrophil-to-lymphocyte and neutrophil-to-T cell ratios, as determined by
156 absolute cell count (Figure 1F, Supplemental Figure 1B). We observed an opposite trend for
157 basophils, which was associated with disease severity, while we did not detect any significant
158 alteration in the eosinophil to lymphocyte or eosinophil to T cell ratios (Figure 1F,
159 Supplemental Figure 1B).

160 This set of data highlights that the granulocyte expansion observed during acute SARS-CoV-
161 2 infection is dominated by neutrophils and is coupled to the reduction of the physiological
162 levels of circulating eosinophils and basophils.

163

164 *Severe COVID-19 is characterized by the emergence of immature neutrophils in peripheral*
165 *blood*

166 Neutrophils have been shown to display a high degree of phenotypical heterogeneity, which
167 has important implications on their function in several pathological contexts (30). Different

168 neutrophil maturation states are associated with major phenotypic differences, e.g. CD16
169 upregulation during development (23, 30). In COVID-19 patients, particularly in those with
170 severe disease, we observed a robust enrichment of a neutrophil subset characterized by low
171 expression of CD16 suggesting that these were immature CD16^{dim} neutrophils (Figure 2A).

172 A significant increase in absolute numbers was detected for both CD16^{bright} and CD16^{dim}
173 neutrophil subsets in COVID-19 patients, which positively correlated with disease severity
174 (Figure 2B). In addition, a significant increase in the relative fraction of CD16^{dim} neutrophils
175 was detected, indicating an overall expansion of immature neutrophils in COVID-19 patients
176 (Figure 2C).

177 In order to analyze the phenotypic traits of the neutrophil subsets identified above in an
178 unsupervised way, 30,000 events in the neutrophil gate from each study participant were
179 concatenated and then down-sampled to 0.5 million cells. By integrating the expression of 20
180 phenotypic markers in the UMAP analysis, we observed only modest differences comparing
181 neutrophils from healthy controls and COVID-19 patients, within the UMAP space (Figure
182 2D). In addition, the CD16^{bright} and CD16^{dim} neutrophil subsets from controls and COVID-19
183 patients clustered separately from each other (Figure 2E), indicating substantial phenotypic
184 differences, which did not depend on the disease state.

185 Next, the expression of markers related to neutrophil development, migration and activation
186 was analyzed. The mature CD16^{bright} neutrophil subset was characterized by higher expression
187 of CD177, CD11b, CXCR1, CXCR2 and CD62L compared to the CD16^{dim} population. On the
188 other hand, CD16^{dim} neutrophils were characterized by higher levels of CD66b, LOX-1 and
189 CD24, which are associated to early stages of neutrophil development (31), confirming the
190 immature phenotype of this subset (Figures 2F-G, Supplemental Figures 2A-B).

191 We also observed significant upregulation of CD66b, CD177, CD11b, CXCR4, CD147 (the
192 receptor that binds the spike protein of SARS-CoV-2) and CD63 in mature neutrophils from
193 COVID-19 patients compared to healthy controls, as well as significant downregulation of
194 CXCR2 (Figure 2G, Supplemental Figure 2A). No differences in the expression of markers
195 related to either co-stimulatory or inhibitory functions, such as HLA-DR, CD86 and PD-L1
196 between healthy controls and COVID-19 patients within either neutrophil subset were detected
197 (Figure 2G, Supplemental Figures 2A-B).

198 While the presented analysis showed several phenotypic differences between healthy controls
199 and COVID-19 patients, we were unable to detect prominent alterations between the moderate
200 and severe patients for any of the neutrophil subsets analyzed (Figure 2G, Supplemental Figure
201 2A-B). Such phenotypic similarity between the global neutrophil compartment in moderate
202 and severe COVID-19 patients was confirmed by principal component analysis (PCA) (Figure
203 2H).

204 Collectively, our analysis highlights the accumulation of immature CD16^{dim} neutrophils and
205 the concurrent activation of the mature neutrophil fraction in peripheral blood of COVID-19
206 patients.

207

208 *The abundance of activated neutrophil immunotypes correlates with markers of anti-viral*
209 *immune response in moderate patients*

210 To investigate further whether specific neutrophil phenotypes were associated with disease
211 progression or severity, unsupervised phenograph clustering was performed on neutrophils
212 derived from all study participants (Figure 3A). In total, 27 clusters were identified with a
213 varying prevalence in the three study groups (Figure 3B). Hierarchical clustering based on
214 marker expression was sufficient to group clusters more abundant in moderate patients (i.e.

215 clusters 16, 22 and 27) (Figure 3C). Specifically, these clusters belonged to the CD16^{bright}
216 subset and displayed higher expression levels of CD11b, CD177 and CD66b. On the other
217 hand, clusters that were enriched in severe COVID-19 encompassed the immature CD16^{dim}
218 population and displayed a more heterogeneous phenotype (Figure 3C). In particular, clusters
219 18, 19 and 23, which were more enriched in severe patients, showed lower levels of several
220 activation markers including CD66b, CD11a and CD11b (Supplemental Figure 3A).
221 Correlation of cluster frequencies in each patient with the concentration of 253 serum/plasma
222 factors (Supplemental Table 4) followed by hierarchical clustering highlighted specific
223 correlation patterns associated with trends in cluster enrichment within specific disease groups
224 (Figure 3D). In particular, clusters 16, 22 and 27, which were enriched in moderate COVID-
225 19, displayed a positive correlation with several molecules of type 1 response (CXCL9,
226 CXCL10 and IL-15), anti-viral response (interferon regulatory factor 9 (IRF9), IL-12p70 and
227 interferon- γ (IFN γ)) and adaptive immunity (B-cell activating factor (BAFF) and IL-2) (Figure
228 3D). In addition, key molecules involved in eosinophil/basophil homeostasis and recruitment
229 (IL-5, CCL3 and stem cell factor (SCF)) were also positively correlated with these clusters.
230 Within the clusters associated with severe patients, several members of the coagulation cascade
231 (Factor VII, VIII and IX) and molecules associated with neutrophil maturation (i.e.
232 granulocyte-colony stimulating factor (G-CSF) and myeloperoxidase (MPO)) were positively
233 correlated (Figure 3D). Shared patterns within cluster groups (e.g. 22, 27 and 5, 23) were also
234 observed when separately analyzing correlations in moderate and severe COVID-19
235 (Supplemental Figure 3B and Supplemental Table 5), suggesting that the degree of disease
236 severity could influence relationships between specific neutrophil immunotypes and soluble
237 factors.

238 In summary, the phenograph-guided in-depth dissection of the neutrophil subset composition
239 allowed us to identify selected immunotypes associated with high circulating levels of
240 prototypical molecules of type-1 related anti-viral immune response.

241

242 *Eosinophil activation profile in COVID-19 correlates with markers of anti-viral immune*
243 *response*

244 Through UMAP analysis integrating the expression of 21 surface markers on eosinophils, we
245 observed that eosinophils from healthy donors clustered separately from the eosinophils of
246 patients with COVID-19 (Figure 4A), indicating significant phenotypic alterations in the
247 eosinophil populations upon SARS-CoV-2 infection. Eosinophils from COVID-19 had
248 decreased expression of the markers of the eosinophil lineage (CD15, CD66b and CD193) (32)
249 and higher expression of classical activation markers, such as CD62L, CD69, as well as CD147
250 (Figure 4B, Supplemental Figure 4A). Phenotypic analysis showed differences between
251 healthy controls and COVID-19 patients, but also between patients with moderate and severe
252 COVID-19 for some of the parameters analyzed. Patients with moderate COVID-19 expressed
253 significantly higher levels of CD66b, CD11b, CD11a and CD24 compared to patients with
254 severe COVID-19 (Figure 4C, Supplemental Figure 4B). Notably within the severe group, the
255 deceased patients had the highest CD69 expression (Figure 4C). PCA analysis recapitulated
256 these differences, highlighting CD193, CD66b, CD11a, CD24, CXCR4 and CD62L as the
257 mostly affected parameters in eosinophils from COVID-19 patients (Figure 4D).

258 We observed that patients with COVID-19 also had a significantly increased frequency of
259 CD69⁺ eosinophils (Figures 4E-F). Indeed, despite the strong eosinopenia (Figure 1D), the
260 absolute counts of CD69⁺ eosinophils were not significantly altered in COVID-19 patients
261 (Figure 4F). CD69⁺ eosinophils displayed significantly higher expression of CD66b, CD147,

262 CD11b and CD193, compared to the corresponding CD69⁻ counterpart, confirming their
263 activation state (Figures 4G-H, Supplemental Figure 4D). Despite their CD69 expression,
264 activated eosinophils from severe COVID-19 patients displayed lower CD11a, CD66b, and
265 CD147 expression compared to CD69⁺ eosinophils from the group with moderate disease
266 (Figures 4G-H, Supplemental Figure 4D), suggesting a partial functional impairment of
267 eosinophils in the more severe COVID-19 stages.

268 The absolute counts of eosinophils in blood correlated inversely with the peripheral levels of
269 SCF and molecules involved in cell response to viral infection, such as DDX58 (DEXD/H-Box
270 Helicase 58, also known as RIG-I), IFN γ and CXCL10 (Figure 4I). Conversely, the eosinophil
271 levels in blood correlated positively with the levels of Interleukin-1 receptor-associated kinase
272 1 (IRAK1), latency associated peptide-transforming growth factor β 1 (LAP-TGF β 1),
273 chemoattractants CCL13, CCL17 and CXCL6 and the coagulation factor VIII (Figure 4I). The
274 frequency of CD69⁺ eosinophils correlated positively with the levels of molecules related to
275 IFN γ , CCL2, CCL7, CCL8, Pentraxin-3, leukemia inhibitory factor receptor (LIFR), as well
276 as PD-L1. sCD163 correlated negatively with the frequency of CD69⁺ eosinophils but
277 positively with the absolute counts and frequencies of eosinophils. Representative plots of the
278 most significantly correlated parameters are shown in Supplemental Figure 4E, while the most
279 significant correlations for the moderate and severe groups separately are shown in
280 Supplemental Figure 4F. In conclusion, our results indicate that the eosinophils in the blood of
281 patients with COVID-19 are activated in response to SARS-CoV-2 infection and express high
282 levels of key receptors for lung tissue infiltration, particularly in patients with moderate
283 COVID-19.

284

285 *Basophils in COVID-19 patients display an activated phenotype*

286 UMAP analyses revealed distinctive clusters in the healthy controls and COVID-19 patients,
287 suggesting alterations in basophil phenotype during the disease (Figure 5A). Specifically,
288 clusters associated with COVID-19 had higher expression of markers important for the
289 activation and recruitment of basophils, including CD11b, CD63, and CXCR4 (Figure 5B;
290 Supplemental Figure 5A). Specific upregulation of CD62L, CD147 and CD177 were observed
291 on basophils from moderate COVID-19 patients (Figure 5C, Supplemental Figure 5B). On the
292 other hand, PD-L1 expression was reduced in all patients compared to healthy controls. The
293 differences in marker expression on basophils between healthy controls and COVID-19
294 patients were further confirmed by PCA, with CXCR4, CD62L, CD193 and PD-L1 among the
295 most contributing parameters driving the separation (Figure 5D). We further examined the
296 correlation of basophils with soluble factors (Figure 5E, Supplemental Figure 5D-E). The
297 basophil frequency was negatively correlated with soluble DDX58, and with the transcription
298 factors amphiregulin (AREG), FOSB and Zinc finger and BTB domain-containing protein 16
299 (ZBTB16). Similar to eosinophils, basophil frequency was also negatively correlated with
300 CCL7. In contrast, CCL22, CCL28 and Fms-related tyrosine kinase 3 ligand (Flt3L) were
301 positively correlated to basophil frequency, particularly in COVID-19 patients with moderate
302 disease (Figure 5E, Supplemental Figure 5E). Other soluble factors that were also positively
303 associated with basophil frequency were CD83 and tumor necrosis factor-related apoptosis-
304 inducing ligand (TRAIL). In summary, the data show that basophils are depleted in COVID-
305 19 patients, a pattern associated with disease severity, and that circulating basophils from
306 patients display an activated phenotype.

307

308 *Eosinophil activation and neutrophil maturation contribute to predictive models of Sequential*
309 *Organ Failure Assessment (SOFA) score and respiratory function*

310 Our well-defined patient cohort allowed us to compare in detail the phenotypic alterations in
311 granulocyte subsets in relation to severity of COVID-19 (Supplemental Table 1). In order to
312 elucidate the underlying relationships between immune traits and relevant clinical parameters
313 registered during hospitalization, we performed multivariate linear regression. The models
314 were based on a comprehensive data set including surface marker expression levels, absolute
315 numbers, frequencies of granulocyte subsets, available clinical information and laboratory
316 measurements. The final set of variables used in the predictive models were selected based on
317 their correlation with the tested clinical outcomes and their relevance in the specific predictive
318 models (Figure 6A).

319 The analysis revealed that the levels of CD11a expression on eosinophils contributed to the
320 linear model for prediction of SOFA score for patients included in our study (Adj. $R^2=0.74$,
321 $p=3.8 \times 10^{-6}$, Figure 6B). Notably, the relevance of CD11a expression on eosinophils was higher
322 in predicting the SOFA score (explaining around 50% of the model) than the levels of two
323 laboratory parameters CRP and creatinine (Figure 6C).

324 We also developed models for prediction of respiratory function including $\text{PaO}_2/\text{FiO}_2$ (P/F)
325 ratio at baseline and maximum oxygen need during hospitalization. The linear model for P/F
326 ratio prediction (Adj. $R^2=0.60$, $p=1.9 \times 10^{-4}$, Figure 6D) included contributions of CD69
327 expression on CD16^{dim} neutrophils, of CD66b on eosinophils and of CRP. The linear model
328 for maximum level of oxygen administration encompassed absolute numbers of mature
329 neutrophils, CD66b expression on eosinophils and ferritin levels (Adj. $R^2=0.74$, $p=3.9 \times 10^{-6}$,
330 Figure 6F). Notably, both models revealed a correlation between CD66b expression on
331 eosinophils and degree of respiratory failure during COVID-19. Moreover, the combined effect
332 of the immune parameters in both models was dominant, contributing to almost 80% of each
333 model (Figures 6C, 6E and 6G). Correction for relevant parameters (e.g. age, BMI, sex, co-
334 morbidities) did not significantly alter any of the linear models or the contribution of the

335 immune cell populations to them, further strengthening the link between granulocyte activation
336 and clinical outcome (Supplemental Table 6). In summary, by applying a supervised machine-
337 learning method we identified eosinophil activation and mature neutrophil counts to be strongly
338 correlated to SOFA score and maximum oxygen need. These immunological signatures,
339 together with other known laboratory markers, but not alone (Supplemental Figure 6), were
340 sufficient to create predictive models.

341

342 *The phenotype of granulocytes is partly restored in patients who have recovered from COVID-*
343 *19*

344 To determine whether the phenotypical alterations observed within the granulocyte
345 compartment during acute COVID-19 were recovered after viral clearance, whole blood
346 samples were collected from the same moderate (n=8) or severe (n=7) patients approximately
347 four months (median=136 days, range=89-153 days) after hospital discharge (Figure 7A).
348 Convalescent samples displayed normalized cell counts for neutrophils, eosinophils and
349 basophils, as well as neutrophil-to-lymphocyte ratio, compared to the samples collected during
350 acute viral infection (Figure 7B, Supplemental Figure 7A), while the relative abundance of the
351 granulocyte subsets over total leukocytes was only partially restored (Figure 7C), suggesting
352 that circulating non-granulocytic immune cells might still be quantitatively affected.
353 Nevertheless, both absolute numbers and frequencies of granulocyte subsets in convalescent
354 patients were very similar to those observed in healthy controls (Figures 7B-C). Additionally,
355 PCA highlighted that convalescent patients were markedly more similar to healthy controls
356 than to acute patients (Figure 7D). In particular, CD69 and CD193 expression on eosinophils,
357 as well as CD147 expression on neutrophils and eosinophils, and basophil counts were among
358 the variables contributing to the observed clustering (Figures 7E-F, Supplemental Figure 7B).

359 Immature CD16^{dim} neutrophils, elevated in acute COVID-19, were almost absent in
360 convalescence (Figure 7G). Neutrophils from convalescent patients showed normalized levels
361 of CXCR1, CXCR4 and CD147 compared to acute infection (Figure 7H, Supplemental Figure
362 7C). Eosinophil activation was also reduced in convalescent patients, as shown by the
363 normalized expression of CD69, CD62L, CD63, and CD147, as well as by the increased PD-
364 L1 expression (Figures. 7I-J, Supplemental Figure 7D). However, the expression of CD66b,
365 CD15 and CD193 on eosinophils was not completely recovered in convalescent samples when
366 compared to healthy controls (Figure 7J, Supplemental Figure 7D), suggesting that a partial
367 phenotypic impairment might still be present in the eosinophil population. Similarly, basophils
368 in the convalescent samples showed an overall recovery of several phenotypic traits altered in
369 acute COVID-19. In particular, the expression levels of CD11b, CD63, CXCR4, and PD-L1
370 (Figures 7K-L, Supplemental Figure 7E) were in line with the levels found in healthy controls.
371

372 **Discussion**

373 The reported clinical relevance of the inflammatory state in the more severe forms of COVID-
374 19 has raised an unprecedented awareness on the potential detrimental role of
375 polymorphonuclear cells in acute viral infections (19). However, a comprehensive phenotypic
376 description performed at the protein level on circulating granulocytes in SARS-CoV-2-infected
377 patients is still lacking. In this report, we show that immature CD16^{dim} neutrophils accumulate
378 in peripheral blood of COVID-19 patients and confirm that general neutrophilia can be
379 considered a hallmark of severe COVID-19. However, in contrast to the tenet linking
380 neutrophil activation with more severe clinical conditions, our approach based on high-
381 dimensional flow cytometry was able to identify activated neutrophil immunotypes detected
382 preferentially in moderate patients showing a better clinical outcome. Furthermore, we
383 extended our analysis to other granulocyte subsets, reporting the substantial ablation of both
384 eosinophils and basophils in peripheral blood of COVID-19 patients. Such depletion could
385 possibly result from two, non-mutually exclusive phenomena: first, both cell types might be
386 recruited to inflamed tissues, and in particular to the lung. This hypothesis is supported by the
387 relevant expression changes of several adhesion/migration molecules (e.g. CD62L, CD11a/b
388 and CXCR4) on both eosinophils and basophils. Moreover, concentrations of key soluble
389 factors involved in the recruitment of both granulocyte subsets (e.g. CCL13, CCL17, CCL22
390 and CCL28) (33) correlated with their levels in circulation. A second explanation for the
391 detected basopenia/eosinopenia in favor of an expanded neutrophil compartment might imply
392 the re-programming of the granulocyte precursor in the bone marrow which typically occurs
393 during emergency hematopoiesis (34).

394 The release of immature neutrophils in circulation has been observed in previous studies
395 investigating a variety of viral infections, including HIV, dengue and SARS-CoV-2 (18, 19,
396 35-38) and is strictly associated with emergency granulopoiesis. Recent studies included CD63

397 mRNA levels in an immature pro/pre-neutrophil signature (31), which was found significantly
398 enriched in COVID-19 patients (19). In this regard, we found a robust CD63 upregulation on
399 CD16^{dim} neutrophils and a further increased expression in COVID-19 patients. Both moderate
400 and severe COVID-19 patients were characterized by the progressive expansion of CD16^{dim}
401 neutrophils, which also expressed lower levels of CD177, CD11b and CD62L and higher levels
402 of CD66b and LOX-1, a phenotype compatible with neutrophil immaturity (31).

403 Our in-depth phenograph-guided analysis of the neutrophil compartment revealed the
404 enrichment of activated neutrophil immunotypes in moderate COVID-19 patients, associated
405 with higher circulating levels of molecules involved in the IFN-mediated anti-viral response
406 (i.e. IRF9, IL-12b, IFN γ). Neutrophils are known to be highly responsive to type I IFN in
407 different contexts (39, 40) and recent studies described the existence of an IFN-responsive,
408 developmentally distinct, neutrophil subset (41). Intriguingly, we observed a positive
409 correlation between type 1 inflammatory mediators (e.g. IFN γ and CXCL10) and eosinophil
410 activation, suggesting that, particularly in moderately affected patients, part of the granulocyte
411 compartment could be actively participating in the efficient viral clearance, similarly to what
412 occurs upon influenza infection (42, 43). Interestingly, CD62L expression on eosinophils can
413 be triggered by IFN γ , and CD62L-expressing eosinophils have been suggested to contribute to
414 dysregulated inflammation and ARDS in acute COVID-19 (24, 44).

415 Eosinophils have been reported to express receptors that allow the recognition and
416 orchestration of anti-viral responses to respiratory viruses (43, 45, 46). Eosinophil-associated
417 lung pathology has been reported in other viral infections and in SARS-CoV-1 vaccination
418 studies (summarized in (47)). On the other hand, the role of human basophils in viral infections
419 is poorly understood and mainly focused on basophil response to HIV (48, 49). CXCR4 is one
420 of the most highly expressed basophil receptors in COVID-19 patients in our cohort and might
421 be implicated in basophil trans-endothelial migration (49). CD63 expression on basophils can

422 be induced by cross-linking of CD62L and CD11b, amongst other stimuli (50). Therefore, the
423 upregulation of CD62L, CD63, CD11b, and CXCR4 on basophils observed during the acute
424 phase of COVID-19 and their normalization after viral clearance might imply a role of this
425 phenotype in COVID-19 pathophysiology.

426 In contrast to the neutrophil phenotypes observed in moderate COVID-19, the neutrophil
427 clusters enriched in patients with severe disease correlated with several coagulation factors and
428 with molecules involved in neutrophil maturation (G-CSF and MPO), but not with any of the
429 screened anti-viral response-related molecules. This suggests an impaired neutrophil response
430 during the more severe phases of the disease. Notably, we did not detect evident signs of
431 immune-suppressive activity (e.g. PD-L1 expression) in our phenotypic analysis, and direct
432 functional evidence will be crucial to assess whether increased suppressive functions are
433 triggered in neutrophils in severe COVID-19 patients. In addition, despite their CD69
434 expression, activated eosinophils in severe COVID-19 patients displayed lower levels of
435 CD11a, CD63, and CD66b compared to the CD69⁺ eosinophils from patients with moderate
436 COVID-19. This phenotype is indicative of activated eosinophils suggesting that they might
437 have recently degranulated (32, 51). Overall, our analyses showed that the robust activation
438 observed in the granulocyte compartment in moderate COVID-19 declines in the more severe
439 stages of the disease.

440 Combination of eosinopenia with elevated CRP could effectively triage suspected patients with
441 COVID-19 from other patients with fever (52). A relevant finding emerging from our study is
442 that selected granulocytic phenotypical traits could, in concert with other known laboratory
443 markers such as CRP or creatinine, predict to a significant extent, key clinical outcomes,
444 including respiratory functionality and SOFA score. Although this finding needs to be taken
445 with caution considering the limited size of our patient cohort, we provide the proof-of-
446 principle that the combination of immunological, and specifically granulocyte-related,

447 measurements with standard clinical data could be used in generating algorithms for patient
448 classification and, thus, tailored therapeutic regimens. Notably, the immunological parameters
449 were predominant in driving the prediction models in comparison to standard laboratory
450 measurements. On the same lines, we connected clinical manifestations, such multi-organ
451 failure and pulmonary function, with specific phenotypes, primarily the eosinophil activation
452 markers CD11a, CD66b, and CD69. Future studies will be important to assess and validate
453 whether there is a mechanistic link between granulocyte activation and specific clinical features
454 of COVID-19 patients.

455 Finally, by taking advantage of paired longitudinal sampling, we report the almost complete
456 phenotypic recovery upon viral clearance of the phenotypic alterations observed in
457 granulocytes from acute SARS-CoV-2 infection. Our findings are in agreement with previous
458 studies showing the replenishment of the eosinophil and basophil pool and the normalization
459 of neutrophil numbers in circulation (24, 53). The current study, however, is the first to
460 characterize in depth the eosinophil and basophil profile in patients with COVID-19 and their
461 phenotypic alterations linked to disease. This is emphasized by the finding that six out of the
462 ten most significant immunological parameters that drive the separate clustering of patients
463 with acute COVID-19 from matched convalescent samples or healthy controls are eosinophil
464 traits. However, the expression of a set of markers (CD15, CD66b, and CD193) was not
465 completely recovered in convalescent samples when compared to non-infected healthy
466 controls, suggesting a partial remaining phenotypic impairment in the granulocyte population
467 in convalescent samples, at least four months after hospital discharge.

468 The inference of mechanisms driving COVID-19 immunopathology from the analysis of
469 circulating granulocytes might have limitations when considering the pulmonary damage
470 displayed in COVID-19 patients. However, several studies have shown that the combined use
471 of peripheral immune signatures, soluble factors and patient metadata retain the capacity to

472 predict clinical outcome to a notable extent (6, 53). Moreover, accumulating evidence indicates
473 that other tissues (e.g. kidney, gut, brain) are affected by COVID-19-related immune
474 alterations, thus underscoring the systemic nature of this disease and emphasizing the relevance
475 of studying alterations in peripheral immune cells (54). Our findings highlight the significant
476 alterations of granulocyte subpopulations in frequency and function in the blood of patients
477 with COVID-19. Moreover, our data indicate the potential contribution of granulocytes to
478 SARS-CoV-2 immunopathology and point towards the combined use of granulocyte-related
479 immunological parameters and basic clinical laboratory tests as better prognostic biomarkers
480 of disease severity and disease course.

481

482 **Materials and Methods**

483 **Study cohort**

484 SARS-CoV-2 infected patients with COVID-19 admitted at the intensive care or high
485 dependency unit (n=16, severe COVID-19) or the infectious disease clinic (n=10, moderate
486 COVID-19) at Karolinska University Hospital, Stockholm, Sweden, were recruited to this
487 study. Serum and EDTA blood samples were collected and analyzed. Inclusion and exclusion
488 criteria for patient enrollment and collected clinical information and laboratory values of the
489 patients are provided in Supplemental Tables 1-3. Convalescent serum and EDTA samples
490 were later collected from 15 patients (8 and 7, from the moderate and severe groups,
491 respectively) approximately 4 months after hospital discharge (median=136 days, range=89-
492 153 days). As controls, serum and blood samples from age- and sex-matched SARS-CoV-2
493 IgG seronegative healthy volunteers (Supplemental Table 1) were collected on the same days
494 as the acute COVID-19 (n=17) and convalescent (n=11) patients. All samples were processed
495 using the same standardized operating procedures. Informed consent was obtained from all
496 study participants and the study was approved by the regional Ethics Committee in Stockholm,
497 Sweden, and performed in accordance with the Declaration of Helsinki.

498

499 **Absolute counts of leukocytes in peripheral blood**

500 Absolute counts of peripheral blood leukocytes were determined for all study participants using
501 BD Trucount tubes (6-color TBNK Reagent and, in addition, CD123 BUV395 (BD
502 Biosciences), CD15 PB, CD193 BV605 and HLA-DR BV785 (Biolegend) and CD14 PE-Cy5
503 (eBioscience) according to the manufacturer's instructions. Samples were fixed in 1X BD
504 FACS lysing solution (BD Biosciences) for 2h and acquired on a BD FACSymphony A5
505 instrument, equipped with UV (355nm), violet (405 nm), blue (488 nm), yellow/green (561
506 nm) and red (637 nm) lasers. For absolute cell count calculations, the number of events for

507 populations of interest was divided by the number of bead events and multiplied by the BD
508 Trucount bead count.

509

510 **Proximity extension assay**

511 The proximity extension assay technology (PEA), based on Q-PCR quantification of pair-wise
512 binding of oligonucleotide-labeled target antibodies (OLINK AB, Uppsala, Sweden), was used
513 for the quantification of 276 selected soluble factors in serum from the study participants
514 (Supplemental Table 4).

515

516 **Luminex assays**

517 Soluble factors in the serum of the study participants were measured using 4 customized
518 multiplex panels including 36, 12, 15 and 12 analytes covering a range of human inflammatory
519 factors (R&D Systems, UK; Supplemental Table 4). Coagulation factors were measured in
520 plasma using 3 different multiplex panels, including the 6-, 4-, and 3-plex human ProcartaPlex
521 panels (ThermoFisher). Assays were performed according to the manufacturer's guidelines and
522 samples were acquired on a Luminex MAGPIX instrument using xPonent 4.0 software
523 (Luminex).

524

525 **Cell preparation and staining for multicolor flow cytometry**

526 For flow cytometric analysis of polymorphonuclear leukocytes, EDTA whole blood samples
527 from all patients and controls were stained with fluorescently labeled antibodies (Supplemental
528 Table 7). In brief, plasma fractions were removed by centrifugation and cells were washed with
529 FACS buffer (PBS, 5% FCS, 0.05 mM EDTA), followed by 15-minute incubation with a
530 cocktail containing Fc-block (Miltenyi) and fluorescent-labeled antibodies for extracellular
531 staining. Dead cells were excluded using the fixable LIVE/DEAD Yellow Dead Cell Stain Kit

532 (Life Technologies). Red blood cells (RBC) were lysed with fixation/permeabilization working
533 solution (BD Cytotfix/Cytoperm™). For SARS-CoV-2 inactivation, samples were fixed for two
534 additional hours in ultra-pure, methanol-free, 1% formaldehyde (Polyscience). Due to heavy
535 RBC coagulation in COVID-19 patient samples, an additional RBC lysis for 10 min was
536 performed. Samples were acquired on a BD FACSymphony equipped with five lasers (BD
537 Biosciences).

538

539 **Flow cytometry data analysis**

540 Standard flow cytometry data analysis was performed using FlowJo version 10. A
541 compensation matrix for the 25-color flow cytometry panel was generated using AutoSpill
542 (55), optimized and applied to all fcs files. All data was pre-processed using the time gate.
543 Following exclusion of doublets and dead cells, neutrophils were defined as $CD15^+CD193^-$
544 $CD66b^+CD16^{bright/dim}$, eosinophils were defined as $CD15^{bright/dim}CD193^{bright/dim}CD16^-$
545 $FcER1^{dim}CD123^{dim/-}$ and basophils were defined as $CD15^-$
546 $CD193^{bright}FcER1^{bright}CD123^{bright}HLA-DR^{dim/-}$. In addition, exclusion of potential
547 contamination by non-granulocytes was done using lineage exclusion markers (CD3, CD14,
548 CD19, CD56, CD304). Samples containing less than 30 events in the final granulocyte subset
549 gate were not considered for further phenotypical analysis. The Cytonorm FlowJo plugin v1.0
550 was applied on each granulocyte population to correct for potential batch effects and was based
551 on an internal control that was sampled on all sampling occasions. Dimensionality reduction
552 was performed with the UMAP FlowJo plugin v3.1. Neutrophil populations from each
553 individual were down-sampled for comparability (FlowJo Downsample plugin v3.3), barcoded
554 and concatenated. FlowJo Phenograph v3 was used for unsupervised clustering.

555

556 **Statistical analysis**

557 GraphPad Prism version 9 (GraphPad Software) and R v4.0.1 (56) were used to conduct
558 statistical analyses, where p-values < 0.05 were considered significant. Two-tailed and non-
559 parametric Mann-Whitney *U* test was used for two-group comparisons. Non-parametric
560 Kruskal-Wallis test, in combination with two-stage step-up method of Benjamini, Krieger and
561 Yekutieli for controlling False Discovery rate (FDR), was used for multiple-group
562 comparisons. Paired samples were analyzed with Wilcoxon matched-pairs signed rank test. For
563 correlations, the two-tailed non-parametric Spearman test was applied. Where indicated, z-
564 score of median fluorescence intensity (MFI) was calculated as follows: $z = (x - \mu) / \sigma$, being $x =$
565 raw score, $\mu =$ mean of sample distribution and $\sigma =$ standard deviation. Correlation, hierarchical
566 clustering and multivariate analysis of flow cytometry data with clinical parameters and
567 proteomic data was performed and visualized in GraphPad Software and R v4.0.1 and v1.3.959
568 (56), using the packages factoextra (v1.0.7) (57), FactoMineR (v2.3) (58),
569 PerformanceAnalytics (v2.0.4) (59), ggplot2 (v3.3.1) (60), gplots (v3.0.4) (61), pheatmap
570 (v1.0.12) (62), vegan (v2.5-6) (63), corrplot (v0.84) (64), lattice (v0.20-41) (65) and
571 latticeExtra (v0.6-29) (66), stats (v4.0.1) and complexheatmap (v2.5.6) (67).

572

573 **Multivariable linear regression**

574 Predictive models for clinical outcomes were built based on a data set of 167 immune traits
575 that included surface marker expression levels, absolute numbers, frequencies of granulocyte
576 subsets, available clinical information and laboratory measured parameters. The creation of the
577 models was performed in R v. 3.6.0 (56). Variable redundancy was avoided by identification
578 of variables with pair-wise spearman correlation coefficient higher than 0.99 (function cor from
579 package stats), and removal of the variable with the largest mean absolute correlation. The
580 remaining variables were pair-wise correlated with the clinical outcome, and those with p-

581 values < 0.05 were selected for further evaluation. All possible linear combinations of variables
582 were evaluated with the function `regsubsets` from the package `leaps` (68) using an ‘exhaustive’
583 method and evaluating 3 subsets per model size. The models with highest adjusted R^2 , lowest
584 bayesian information criterion and a Mallows’ C_p lower and closer to the number of
585 coefficients, were selected for further evaluation. The variance inflation factor for each model
586 was calculated to avoid redundancy in the independent variables with the function `var` from
587 package `car` (69). The selected final model had no redundant variables, and all must be
588 significant ($p\text{-value} < 0.05$). The contribution of each parameter to each model was calculated
589 with the functions `cal.relimp` from package `relaimpo` (70) with the `lgm` metric. Differences in
590 the model after addition of factors for correction (sex, age, BMI, smoking, days from symptom
591 to sampling and from admission to sampling and co-morbidities) were evaluated by computing
592 an analysis of variance for the two linear models.
593

594 **Author contributions**

595 Conceptualization: ML, MD, LH, AP, ANT, BJC. Methodology: ML, MD, LH, LMPM.
596 Investigation: ML, MD, LH, LMPM, PC, JRM, J-BG, JE, KMo, MG, KMa. Data analysis: ML,
597 MD, LH, HB, LMPM, EK, MC, AP. Patient recruitment and clinical information: EF, SGR,
598 AS, LIE, OR, SA, KS, H-GL, NKB. Organization of sample handling and other resources: PC,
599 JK, JM_i, MFT, SB, MB, JM_j, K-JM, JS, J-IH and the Karolinska KI/K COVID-19 Study Group.
600 Writing (original draft): ML, MD, LH, HB, LMPM, AP, BJC, ANT. Writing (review and
601 editing): All authors. Supervision of experiments: ML.

602

603 **Acknowledgements**

604 We thank all patients and healthy donors for their generous participation.

605 See Supplemental Acknowledgments for Karolinska KI/K COVID-19 consortium details. The
606 study was supported by grants from Nordstjernan AB and Knut and Alice Wallenberg
607 Foundation to H-GL, the Swedish Governmental Agency for Innovation Systems (VINNOVA)
608 under the frame of NordForsk (Project no. 90456, PerAID) and the Swedish Research Council
609 under the frame of ERA PerMed (Project 2018-151, PerMIT) to ANT, the Swedish Research
610 Council to BJC and AP, the Swedish Cancer Foundation to BJC, Clas Groschinsky Foundation,
611 Centrum for Innovative Medicine to AP and ANT, the Swedish Children's Cancer Foundation
612 (TJ2018-0128 and PR2019-0100) to ML, Åke Olsson Foundation to ML and AP and KI
613 Research Foundation to ML, LH and AP.

614

615 **Data and material availability**

616 Curated flow cytometry data will be made available for exploration via the KI/K COVID-19
617 Immune Atlas, <http://covid19cellatlas.com/>. All other data needed to evaluate the conclusions
618 of the paper are presented in the paper or in the Supplemental Material.

619 **References**

- 620 1. Guan WJ, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl*
621 *J Med.* 2020;382(18):1708-1720.
- 622 2. Wu Z, and McGoogan JM. Characteristics of and Important Lessons From the
623 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
624 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA.* 2020.
- 625 3. Mehta P, et al. COVID-19: consider cytokine storm syndromes and
626 immunosuppression. *Lancet.* 2020;395(10229):1033-1034.
- 627 4. Yang Y, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease
628 severity and predict the progression of COVID-19. *J Allergy Clin Immunol.*
629 2020;146(1):119-127 e114.
- 630 5. Blanco-Melo D, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development
631 of COVID-19. *Cell.* 2020;181(5):1036-1045 e1039.
- 632 6. Lucas C, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-
633 19. *Nature.* 2020.
- 634 7. Mantovani A, et al. Neutrophils in the activation and regulation of innate and adaptive
635 immunity. *Nat Rev Immunol.* 2011;11(8):519-531.
- 636 8. Liu J, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles
637 in the peripheral blood of SARS-CoV-2 infected patients. *EBioMedicine.*
638 2020;55:102763.
- 639 9. Channappanavar R, et al. Sex-Based Differences in Susceptibility to Severe Acute
640 Respiratory Syndrome Coronavirus Infection. *J Immunol.* 2017;198(10):4046-4053.
- 641 10. Alfaraj SH, et al. Clinical predictors of mortality of Middle East Respiratory Syndrome
642 Coronavirus (MERS-CoV) infection: A cohort study. *Travel Med Infect Dis.*
643 2019;29:48-50.

- 644 11. Lee JJ, et al. Human versus mouse eosinophils: "that which we call an eosinophil, by
645 any other name would stain as red". *J Allergy Clin Immunol.* 2012;130(3):572-584.
- 646 12. Camp JV, and Jonsson CB. A Role for Neutrophils in Viral Respiratory Disease. *Front*
647 *Immunol.* 2017;8:550.
- 648 13. Miura TA, and Holmes KV. Host-pathogen interactions during coronavirus infection of
649 primary alveolar epithelial cells. *J Leukoc Biol.* 2009;86(5):1145-1151.
- 650 14. Karasuyama H, et al. Multifaceted roles of basophils in health and disease. *J Allergy*
651 *Clin Immunol.* 2018;142(2):370-380.
- 652 15. Rosenberg HF, et al. Eosinophils and their interactions with respiratory virus pathogens.
653 *Immunol Res.* 2009;43(1-3):128-137.
- 654 16. Liao M, et al. Single-cell landscape of bronchoalveolar immune cells in patients with
655 COVID-19. *Nat Med.* 2020;26(6):842-844.
- 656 17. Chua RL, et al. COVID-19 severity correlates with airway epithelium-immune cell
657 interactions identified by single-cell analysis. *Nat Biotechnol.* 2020.
- 658 18. Wilk AJ, et al. A single-cell atlas of the peripheral immune response in patients with
659 severe COVID-19. *Nat Med.* 2020.
- 660 19. Schulte-Schrepping J, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid
661 Cell Compartment. *Cell.* 2020;182(6):1419-1440 e1423.
- 662 20. Agrati C, et al. Expansion of myeloid-derived suppressor cells in patients with severe
663 coronavirus disease (COVID-19). *Cell Death Differ.* 2020.
- 664 21. Hadjadj J, et al. Impaired type I interferon activity and inflammatory responses in severe
665 COVID-19 patients. *Science.* 2020.
- 666 22. Silvestre-Roig C, et al. Neutrophil Diversity in Health and Disease. *Trends Immunol.*
667 2019;40(7):565-583.

- 668 23. Jaillon S, et al. Neutrophil diversity and plasticity in tumour progression and therapy.
669 *Nat Rev Cancer*. 2020.
- 670 24. Rodriguez L, et al. Systems-Level Immunomonitoring from Acute to Recovery Phase
671 of Severe COVID-19. *Cell Rep Med*. 2020;1(5):100078.
- 672 25. Sekine T, et al. Robust T Cell Immunity in Convalescent Individuals with
673 Asymptomatic or Mild COVID-19. *Cell*. 2020;183(1):158-168 e114.
- 674 26. Maucourant C, et al. Natural killer cell immunotypes related to COVID-19 disease
675 severity. *Sci Immunol*. 2020;5(50).
- 676 27. Parrot T, et al. MAIT cell activation and dynamics associated with COVID-19 disease
677 severity. *Sci Immunol*. 2020;5(51).
- 678 28. García M, et al. Innate lymphoid cell composition associates with COVID-19 disease
679 severity. *Clinical & Translational Immunology*. 2020;9(12):e1224.
- 680 29. Liu J, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019
681 coronavirus disease in the early stage. *J Transl Med*. 2020;18(1):206.
- 682 30. Ng LG, et al. Heterogeneity of neutrophils. *Nat Rev Immunol*. 2019;19(4):255-265.
- 683 31. Kwok I, et al. Combinatorial Single-Cell Analyses of Granulocyte-Monocyte
684 Progenitor Heterogeneity Reveals an Early Uni-potent Neutrophil Progenitor.
685 *Immunity*. 2020.
- 686 32. Yoon J, et al. CD66b regulates adhesion and activation of human eosinophils. *J*
687 *Immunol*. 2007;179(12):8454-8462.
- 688 33. Yi S, et al. Eosinophil recruitment is dynamically regulated by interplay among lung
689 dendritic cell subsets after allergen challenge. *Nat Commun*. 2018;9(1):3879.
- 690 34. Manz MG, and Boettcher S. Emergency granulopoiesis. *Nat Rev Immunol*.
691 2014;14(5):302-314.

- 692 35. Guo PL, et al. The clinical significance of myeloid-derived suppressor cells in dengue
693 fever patients. *BMC Infect Dis.* 2019;19(1):926.
- 694 36. Silvin A, et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate
695 Severe from Mild COVID-19. *Cell.* 2020;182(6):1401-1418 e1418.
- 696 37. Bowers NL, et al. Immune suppression by neutrophils in HIV-1 infection: role of PD-
697 L1/PD-1 pathway. *PLoS Pathog.* 2014;10(3):e1003993.
- 698 38. Carissimo G, et al. Whole blood immunophenotyping uncovers immature neutrophil-
699 to-VD2 T-cell ratio as an early marker for severe COVID-19. *Nat Commun.*
700 2020;11(1):5243.
- 701 39. Jablonska J, et al. Neutrophils responsive to endogenous IFN-beta regulate tumor
702 angiogenesis and growth in a mouse tumor model. *J Clin Invest.* 2010;120(4):1151-
703 1164.
- 704 40. Mistry P, et al. Transcriptomic, epigenetic, and functional analyses implicate neutrophil
705 diversity in the pathogenesis of systemic lupus erythematosus. *Proc Natl Acad Sci U S*
706 *A.* 2019;116(50):25222-25228.
- 707 41. Xie X, et al. Single-cell transcriptome profiling reveals neutrophil heterogeneity in
708 homeostasis and infection. *Nat Immunol.* 2020.
- 709 42. Tang BM, et al. Neutrophils-related host factors associated with severe disease and
710 fatality in patients with influenza infection. *Nat Commun.* 2019;10(1):3422.
- 711 43. Rimmelzwaan GF, et al. Inhibition of influenza virus replication by nitric oxide. *J Virol.*
712 1999;73(10):8880-8883.
- 713 44. Mesnil C, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil
714 subset. *J Clin Invest.* 2016;126(9):3279-3295.
- 715 45. Flores-Torres AS, et al. Eosinophils and Respiratory Viruses. *Viral Immunol.*
716 2019;32(5):198-207.

- 717 46. Drake MG, et al. Human and Mouse Eosinophils Have Antiviral Activity against
718 Parainfluenza Virus. *Am J Respir Cell Mol Biol*. 2016;55(3):387-394.
- 719 47. Lindsley AW, et al. Eosinophil responses during COVID-19 infections and coronavirus
720 vaccination. *J Allergy Clin Immunol*. 2020;146(1):1-7.
- 721 48. Jiang AP, et al. Human Blood-Circulating Basophils Capture HIV-1 and Mediate Viral
722 trans-Infection of CD4+ T Cells. *J Virol*. 2015;89(15):8050-8062.
- 723 49. Rossi FW, et al. HIV-1 Nef promotes migration and chemokine synthesis of human
724 basophils and mast cells through the interaction with CXCR4. *Clin Mol Allergy*.
725 2016;14:15.
- 726 50. Kalm F, et al. Adhesion molecule cross-linking and cytokine exposure modulate IgE-
727 and non-IgE-dependent basophil activation. *Immunology*. 2021;162(1):92-104.
- 728 51. Rosenberg HF, et al. Eosinophils: changing perspectives in health and disease. *Nat Rev*
729 *Immunol*. 2013;13(1):9-22.
- 730 52. Li Q, et al. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19
731 patients in fever clinic: A retrospective case-control study. *EClinicalMedicine*.
732 2020;23:100375.
- 733 53. Laing AG, et al. A dynamic COVID-19 immune signature includes associations with
734 poor prognosis. *Nat Med*. 2020;26(10):1623-1635.
- 735 54. Vabret N, et al. Immunology of COVID-19: Current State of the Science. *Immunity*.
736 2020;52(6):910-941.
- 737 55. Roca CP, et al. AutoSpill: a method for calculating spillover coefficients in high-
738 parameter flow cytometry. *bioRxiv*. 2020:2020.2006.2029.177196.
- 739 56. Team RC. R: A language and environment for statistical computing. 2019.
- 740 57. Kassambara A, and Mundt F. factoextra: Extract and Visualize the Results of
741 Multivariate Data Analyses. 2020.

- 742 58. Lê S, et al. FactoMineR: An R Package for Multivariate Analysis. *Journal of Statistical*
743 *Software*. 2008;25(1):1-18.
- 744 59. Peterson BG, et al. PerformanceAnalytics: Econometric Tools for Performance and
745 Risk Analysis. 2020.
- 746 60. Wickham H. *ggplot2: Elegant Graphics for Data Analysis*. Springer International
747 Publishing; 2016.
- 748 61. Warnes GR, et al. *gplots: Various R Programming Tools for Plotting Data*. 2020.
- 749 62. Kolde R. *pheatmap: Pretty Heatmaps*. 2019.
- 750 63. Oksanen J, et al. *vegan: Community Ecology Package*. 2020.
- 751 64. Wei T, et al. *corrplot: Visualization of a Correlation Matrix*. 2017.
- 752 65. Sarkar D. *Lattice: Multivariate Data Visualization with R. Use R!* 2008.
- 753 66. Sarkar D, and Andrews F. *latticeExtra: Extra Graphical Utilities Based on Lattice*. 2019.
- 754 67. Gu Z, et al. Complex heatmaps reveal patterns and correlations in multidimensional
755 genomic data. *Bioinformatics*. 2016;32(18):2847-2849.
- 756 68. Lumley T. *leaps: Regression Subset Selection*. Based on Fortran code by Alan Miller.
757 2020.
- 758 69. Fox J, et al. *car: Companion to Applied Regression*. 2020.
- 759 70. Groemping U, and Matthias L. *relaimpo: Relative Importance of Regressors in Linear*
760 *Models*. 2018.
- 761

Figures and figure legends

Figure 1




Figure 1. Disease severity-dependent neutrophilia and marked decrease of eosinophils and basophils in COVID-19. (A) Experimental and analytical workflow of the study performed on samples from moderate and severe COVID-19 patients and age-matched healthy controls. (B) Dot plots (left) and alluvial diagram (right) describing demographics and the clinical characteristics of the patients included in the study cohort. Severity groups (moderate=blue; severe=purple; deceased=gray) are indicated. (C) Gating strategy for the identification of granulocyte subsets and their UMAP projection is shown on the left. On the right, analogue results are obtained through unsupervised subset identification based on UMAP projection of total granulocytes. (D-E) Absolute cell counts (D) and frequencies (E) among total leukocytes for neutrophils, eosinophils and basophils in healthy controls (n=17), moderate COVID-19 patients (n=10) and severe COVID-19 patients (n=16). (F) Ratios of granulocyte absolute counts over lymphocyte absolute counts in healthy controls (n=17), moderate COVID-19 patients (n=10) and severe COVID-19 patients (n=16). In (D-F), Kruskal-Wallis test and two-stage Benjamini, Krieger and Yekutieli test. Bars represent median. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$. Neu, neutrophils; eos, eosinophils; bas, basophils; lymphs, lymphocytes.

Figure 2




Figure 2. Emergence of immature neutrophils in severe COVID-19. (A) Representative plots showing neutrophil identification and CD16^{bright} and CD16^{dim} subset discrimination in different study groups. Absolute cell counts (B) and frequencies (C) among total neutrophils of CD16^{bright} and CD16^{dim} cells in healthy controls (n=17), moderate COVID-19 patients (n=10) and severe COVID-19 patients (n=16). (D) UMAPs on concatenated files (see Methods) of total neutrophils in healthy controls, moderate and severe COVID-19 patients. (E) UMAPs of CD16^{bright} and CD16^{dim} cells within pooled neutrophils from all study groups (30,000 down-sampled cells/individual). (F) Median fluorescence intensity (MFI) of selected surface markers in the UMAP projection described in (D). (G) Heatmap showing the mean normalized marker expression (z-score) in CD16^{bright} and CD16^{dim} neutrophils in healthy

controls (n=17), moderate (n=10) and severe COVID-19 patients (n=16). **(H)** PCA based on marker expression (MFI) on CD16^{bright} and CD16^{dim} neutrophils. **(B)** and **(C)** Kruskal-Wallis test and two-stage Benjamini, Krieger and Yekutieli test. Bars represent median. * $p < 0.05$; ** $p < 0.01$; **** $p < 0.0001$.

Figure 3




Figure 3. Phenograph analysis identifies activated neutrophil subsets correlating with markers of anti-viral immune response in moderate COVID-19 patients. (A) Distribution of the 27 identified phenograph clusters overlaid on the UMAP projection. (B) Frequency of the phenograph clusters within healthy controls (n=17), moderate (n=10) and severe COVID-19 patients (n=16). *, statistically significant differences in comparisons with healthy controls. #, statistically significant differences comparing moderate and severe patients. (C) Heatmap showing normalized expression (MFI z-score) of 20 markers analyzed by flow cytometry in the 27 neutrophil clusters identified in (A). Hierarchical clustering was performed and rows were split by k -means=4. Right annotation shows the log₁₀-ratio of cluster enrichment in moderate (blue) versus severe (purple) COVID-19 patients. (D) Heatmap showing Spearman correlation between phenograph clusters and soluble factors detected in all COVID-19 patients (n=26). Hierarchical clustering was performed, and columns were split by k -means=4. Bottom annotation shows the log₁₀-ratio of cluster enrichment in moderate (blue) versus severe (purple) COVID-19 patients. In (B) Kruskal-Wallis test and two-stage Benjamini, Krieger and Yekutieli test. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.0001$.

Figure 4




Figure 4: Activation of eosinophils in patients with COVID-19. (A) Overall and individual UMAPs on concatenated files (see Methods) of eosinophils in healthy controls, moderate and severe COVID-19 patients. (B) UMAP displaying the MFI of selected markers. (C) MFI of selected eosinophil markers in healthy controls (n=17), patients with moderate (n=8) and severe (n=14) COVID-19. Median values for each group are indicated. (D) PCA based on MFI expression of eosinophil markers. (E) CD69⁺ eosinophils from a representative healthy control and COVID-19 patients. (F) Frequencies and absolute counts of CD69⁺ eosinophils in healthy controls (n=17), moderate (n=8) and severe (n=14) COVID-19 patients. (G) Marker expression (z-score) on CD69⁻ and CD69⁺ subsets. (H) MFI of selected markers in eosinophil subsets in healthy controls (n=15), in moderate (n=8) and severe (n=11) COVID-19 patients. (I) Heatmaps demonstrating correlations (Spearman non-parametric, $r < -0.4$ or $r > 0.4$, $p < 0.05$) between absolute eosinophil counts, frequencies and percent of CD69⁺ eosinophils and soluble factors in COVID-19 patients. Statistical analysis by Kruskal-Wallis test and two-stage Benjamini, Krieger and Yekutieli test (C, F and H) and Wilcoxon matched-pairs signed rank test (H). FDR adjusted p-values are indicated. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$.

Figure 5




Figure 5. Basophils in COVID-19 patients display an activated phenotype. (A) UMAPs on concatenated files (see Methods) showing basophil overview together with representative plots

heathy controls, moderate and severe COVID-19 patients. **(B)** UMAP showing the level of expression of selected markers on basophils. **(C)** MFI for selected markers on basophils in heathy controls (n=17), moderate (n=10) and severe (n=12) COVID-19 patients. Median values for each group are indicated. **(D)** PCA and biplot based on the MFI expression of representative basophil markers in healthy controls, moderate and severe COVID-19 patients. **(E)** Heatmap demonstrating correlation (Spearman non-parametric, $r < -0.4$ or $r > 0.4$, $p < 0.05$) between absolute basophil counts/basophil frequencies of total leukocytes and basophil-associated soluble factors, in COVID-19 patients. Significant differences between healthy controls and patient groups in **(C)** were evaluated with Kruskal-Wallis test and two-stage Benjamini, Krieger and Yekutieli test. FDR adjusted p-values are indicated. * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

Figure 6




Figure 6. Eosinophil activation and neutrophil maturation are relevant for prediction of SOFA score and respiratory function. (A) Diagonal correlation matrix including predicted clinical outcomes (bold) and the explanatory variables included in the final models. (B-G) Multivariate linear regressions for prediction of SOFA score (B-C), PaO₂/FiO₂ (P/F) ratio (D-E) and peak oxygen need (F-G) were modeled based on immune traits and laboratory markers. (B, D, F) Scatter plots of actual values versus predicted values of the linear models. (C, E, G) Individual contribution of the variables included in the final models. Adj R², Adjusted R²; RMSE, Root-mean-square error; Eos, Eosinophils; Neu, Neutrophils.

Figure 7




Figure 7. Granulocyte phenotype in convalescent patients is largely restored. (A) Schematic illustration of paired acute (Ac) and convalescent (Cv) patient samples included in the study. Absolute cell counts (B) and granulocyte frequencies over total leukocytes (C) in paired Ac and Cv patients (n=15). (D) PCA based on cell counts, frequencies and normalized MFI (z-score) of all measured markers. (E) Variable correlation plot. (F) Relative contribution of variables to PC1 and PC2. (G) CD16^{dim} neutrophil frequencies in paired Ac and Cv patient samples (n=15). (H) Expression of selected neutrophil markers in paired Ac and Cv patients (n=15). (I) CD69⁺ eosinophil expression in paired Ac and Cv patients (n=15). (J) Expression of selected eosinophil markers in paired Ac and Cv patient samples (n=15). (K) CXCR4 basophil expression in Ac and Cv patients. (L) Expression of selected basophil markers in paired Ac and Cv patients (n=15). Wilcoxon matched-pairs rank test; ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Healthy controls (n=28, median±IQR) ranges are shown in green. Bars indicate statistical significance considering all sampled patients (black), only moderate (blue) or only severe (purple) patients. Bas, Basophils; Eos, Eosinophils; Neu, Neutrophils.